Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)

29 de abril de 2026 actualizado por: Xingen Zhu, Second Affiliated Hospital of Nanchang University

Construction of an Integrated Intelligent Model for Spontaneous Intracerebral Hemorrhage Based on Deep Learning

Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is still limited to the traditional Tada formula, and there are subjective differences in diagnosis among different doctors, making it difficult to achieve homogenization in clinical decision-making. Hemorrhagic stroke is a common and frequently occurring disease in Jiangxi Province. Therefore, establishing a new diagnosis and treatment system focused on hemorrhagic stroke can not only fill the research gap in this field in China, improve the accuracy and homogeneity of hemorrhagic stroke diagnosis and treatment, but also promote related research progress to reduce the mortality and disability rates of this disease and improve the clinical prognosis of patients.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

Hemorrhagic stroke is a serious cerebrovascular disease, accounting for about 20% of all strokes. It refers to cerebral hemorrhage and subarachnoid hemorrhage caused by intracranial vascular diseases such as intracranial aneurysms, cerebral and spinal vascular malformations and moyamoya disease under the effect of blood flow. It has the characteristics of high incidence rate, high disability rate and high mortality rate, and has caused huge economic burden to patients, families and society.

Hemorrhagic stroke is one of the high-risk diseases in Jiangxi Province, and has become a major public health challenge and a key social issue that urgently needs to be addressed. On the one hand, the diagnosis and treatment of hemorrhagic stroke have a certain degree of complexity, involving multiple disciplines, especially neurology and endocrinology, which have established multiple diagnostic, evaluation, treatment, and rehabilitation systems. Different systems have different focuses, but limited by the level of understanding of the disease, there have been only basic treatment principles for decades, and there has been no breakthrough in specific treatment plans. On the other hand, with the development of the economy and the improvement of living standards, clinical physicians and patients not only focus on the survival rate after hemorrhagic stroke, but also pay more attention to neurological function recovery and long-term quality of life. Due to the limitations of detection technology in the past, it was difficult to accurately describe diseases and truly develop individualized diagnosis and treatment plans, resulting in significant differences in patient prognosis. How to leverage advances in diagnosis and treatment technology to ultimately achieve precision, individualization, and homogenization in the diagnosis and treatment of hemorrhagic stroke is a key focus for the future.

Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is still limited to the traditional Tada formula, and there are subjective differences in diagnosis among different doctors, making it difficult to achieve homogenization in clinical decision-making. Hemorrhagic stroke is a common and frequently occurring disease in Jiangxi Province. Therefore, establishing a new diagnosis and treatment system focused on hemorrhagic stroke can not only fill the research gap in this field in China, improve the accuracy and homogeneity of hemorrhagic stroke diagnosis and treatment, but also promote related research progress to reduce the mortality and disability rates of this disease and improve the clinical prognosis of patients.

Tipo de estudio

De observación

Inscripción (Estimado)

7100

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Ping Hu, PhD;MD
  • Número de teléfono: 13207109734
  • Correo electrónico: hp666edu@163.com

Copia de seguridad de contactos de estudio

  • Nombre: Xingen Zhu, Prof
  • Número de teléfono: 13803546020
  • Correo electrónico: zxg2008vip@163.com

Ubicaciones de estudio

      • Nanchang, Porcelana
        • Reclutamiento
        • The Second Affiliated Hospital of Nanchang University
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Método de muestreo

Muestra no probabilística

Población de estudio

Spontaneous hemorrhagic stroke, including parenchymal hemorrhage, subarachnoid hemorrhage, intraventricular hemorrhage, and subdural hemorrhage(including chronic subdural hemorrhage).

Descripción

Inclusion Criteria:

  1. Age >= 8 years old;
  2. Patients diagnosed with spontaneous hemorrhagic stroke based on medical history and auxiliary examinations;
  3. Received non-contrast computed tomography (NCCT) in the outpatient or emergency department;
  4. Treated in accordance with standard clinical guidelines during hospitalization;
  5. Have complete clinical data.

Exclusion Criteria:

  1. Had undergone surgical treatment in another hospital before admission;
  2. Was in a state of shock upon admission;
  3. Had severe heart, liver, or kidney dysfunction or other life-threatening systemic diseases;
  4. Died during hospitalization;
  5. Had an expected lifespan of less than six months or was unable to complete the study follow-up for other reasons.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Area Under Curve
Periodo de tiempo: 90-day and 180-day
90-day and 180-day mRS score, survival status, functional independence (Barthel index).
90-day and 180-day

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sensitivity ,Specificity,True Positive Rate,False Positive Rate
Periodo de tiempo: Baseline (admission), 24 hours postoperatively, 3 days postoperatively, 7 days postoperatively, discharge, 90-day follow-up, 180-day follow-up
Including hospital stay, ICU stay, hospitalization costs, rebleeding, delayed cerebral ischemia, intracranial infection, and hydrocephalus flow surgery needs
Baseline (admission), 24 hours postoperatively, 3 days postoperatively, 7 days postoperatively, discharge, 90-day follow-up, 180-day follow-up

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de septiembre de 2022

Finalización primaria (Estimado)

1 de agosto de 2026

Finalización del estudio (Estimado)

30 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

29 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

29 de abril de 2026

Publicado por primera vez (Actual)

6 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de abril de 2026

Última verificación

1 de abril de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir